- Home
- ABCL vs EROC Comparison
ABCL vs EROC Comparison
Compare ABCL & EROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABCL | EROC |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ABCL | EROC |
|---|---|---|
| Price | $12.19 | $8.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | $16.82 | ★ $22.13 |
| AVG Volume (30 Days) | ★ 4.3M | 2.9M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,128,000.00 | N/A |
| Revenue This Year | N/A | $146.63 |
| Revenue Next Year | $7.12 | $214.16 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 160.56 | N/A |
| 52 Week Low | $2.75 | $7.65 |
| 52 Week High | $14.98 | $17.98 |
Technical Indicators
Market Signals| Indicator | ABCL | EROC |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 35.31 |
| Support Level | $11.78 | $7.65 |
| Resistance Level | $12.88 | $14.06 |
| Average True Range (ATR) | 0.83 | 0.80 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 40.11 | 12.39 |
Price Performance
Historical ComparisonAbout ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.